Archives
-
Primidone (Mysoline) and TRPM3 in Adenomyosis
2026-10-07
Primidone, also known as Mysoline, is being explored as a repurposing candidate in adenomyosis because of its reported activity at TRPM3, a pain-related ion channel. This overview examines the 2025 study by Jin et al., which combined human tissue profiling with a tamoxifen-induced mouse model. The findings support an association between TRP-channel expression and adenomyosis symptoms and suggest that Primidone reduced pain-related behavior and myometrial infiltration in mice. However, the evidence remains preclinical: the human component was observational, the animal sample was small, and pharmacological treatment alone cannot prove that TRPM3 was the sole mediator. Broader claims involving ALS, RIPK1, or neurodevelopmental disorders require separate primary evidence.
-
Gasdermin C Drives PDAC Stemness and Immune Evasion
2026-10-07
A 2024 Advanced Science study identifies GSDMC as a nuclear regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion, extending its role beyond pyroptosis-associated membrane permeabilization. The work connects ADAM17-dependent cleavage and nuclear translocation of GSDMC to transcriptional reprogramming and reports improved responses to KRASG12D inhibition and PD-1 blockade in preclinical models.
-
Salvianolic Acid B and Pulmonary Fibrosis Evidence
2026-10-06
Salvianolic acid B, also called Dan Shen Suan B, is a natural product being investigated as a pulmonary fibrosis research compound. Current evidence links it to reduced LH2 expression, collagen remodeling, and fibrotic phenotypes in preclinical models, but it does not establish clinical efficacy or direct enzyme inhibition.
-
Panobinostat and the RNF20/RNF40/WAC Axis in MLL-ALL
2026-10-06
The 2018 Leukemia study linked panobinostat treatment to anti-leukaemic activity in MLL-rearranged acute lymphoblastic leukaemia and identified depletion of RNF20/RNF40/WAC-dependent H2B ubiquitination as a relevant molecular event. Its combined xenograft, cellular, and mechanistic evidence supports epigenetic pathway convergence as a therapeutic concept, while remaining limited to preclinical models.
-
Direct Mouse Genotyping Kit Plus in Research
2026-10-05
The Direct Mouse Genotyping Kit Plus is described as a direct-lysis PCR workflow for mouse tissue DNA screening. Its PCR master mix with dye reagents may simplify research genotyping, but the supplied product description does not independently establish assay performance or validate the macrophage EP4 findings reported in Cells.
-
Salvianolic Acid B: A Matrix-Centered Antifibrotic View
2026-10-05
Salvianolic acid B, also known as Dan Shen Suan B, is emerging as a research probe for LH2/PLOD2-associated collagen remodeling in pulmonary fibrosis. This thought-leadership analysis examines the preclinical evidence, translational opportunities, competitive context, and critical limitations behind its proposed antifibrotic mechanism.
-
3X FLAG Peptide: Evidence, Uses, and Limits
2026-10-04
A source-grounded overview of the 3X (DYKDDDDK) Peptide, covering its conceptual role in recombinant protein detection, affinity workflows, and structural biology while separating supplier claims from peer-reviewed or preprint evidence.
-
PreScission Protease for Native Protein Workflows
2026-10-02
PreScission Protease enables defined fusion protein tag cleavage at low temperature, helping researchers prepare cleaner, more native-like proteins for biochemical and interaction assays. This guide connects practical HRV 3C protease workflows with the dKeap1–lamin Dm0 findings and shows how construct design, controlled incubation, and tag removal can improve assay interpretation.
-
Lipid Nanoparticles in Cancer Immunotherapy
2026-10-01
This 2025 review explains how lipid nanoparticles can address degradation, cellular uptake, biodistribution, and toxicity barriers in nucleic acid cancer immunotherapy. Its central contribution is an integrated framework linking cargo selection, nanoparticle properties, immune-cell delivery, and translational limitations rather than introducing a new formulation.
-
Drosophila Keap1–Lamin Dm0 in Nuclear Architecture
2026-10-01
Carlson and colleagues identify a molecular and genetic relationship between Drosophila Keap1 and the B-type lamin Dm0, extending Keap1 biology beyond oxidative and xenobiotic transcriptional responses. Their results connect dKeap1 mis-regulation with lamin redistribution, altered heterochromatin-associated H3K9me2 patterns, nuclear-lamina defects, and developmental viability.
-
Deracoxib and Canine Osteosarcoma Cell Viability
2026-09-30
Royals and colleagues compared Deracoxib with piroxicam in three canine osteosarcoma cell lines and a fibroblast control, finding stronger and more consistent viability inhibition with Deracoxib. The study also showed that reduced viability was not accompanied by detectable DNA fragmentation, separating cytotoxicity from demonstrated apoptosis under the tested conditions.
-
Thymoquinone Workflow for Cardiotoxicity Research
2026-09-30
Build a translational workflow around Thymoquinone to connect cardiac function, oxidative stress, ferroptosis, and mitochondrial injury. The approach combines literature-backed mouse dosing with flexible cell-based optimization, helping researchers distinguish genuine cardioprotection from solvent, assay, or exposure artifacts.
-
Indole-3-pyruvic acid: Applied Research Workflows
2026-09-29
Indole-3-pyruvic acid (IPA) links auxin pathway control with AhR-focused immune assays. This workflow-led guide shows how to handle IPA, select controls, reproduce the rheumatoid arthritis model logic, and troubleshoot plant, fungal, and mammalian experiments.
-
Salvianolic Acid B, LH2, and Pulmonary Fibrosis
2026-09-29
The reference study identifies Salvianolic acid B (Dan Shen Suan B) as a candidate antifibrotic agent that reduces LH2-associated collagen cross-linking and pulmonary fibrotic remodeling. Its integrated cellular and tissue-level design connects LH2 expression with epithelial–mesenchymal transition, fibroblast activation, Wnt/β-catenin signaling, collagen deposition, and lung architecture, while leaving important questions about direct target engagement and clinical translation.
-
Axitinib (AG 013736) Research Workflows
2026-09-28
Build more informative angiogenesis and cancer models with Axitinib (AG 013736), from VEGF-pathway phosphorylation assays to endothelial survival and xenograft studies. A two-metric response strategy helps distinguish cytostatic effects from actual cell killing, improving interpretation of treatment timing and potency.